camrelizumab + etoposide + cisplatin

This combination therapy consists of camrelizumab, a humanized monoclonal antibody targeting programmed death protein 1 (PD-1), and the cytotoxic chemotherapy agents etoposide and cisplatin. Camrelizumab functions as an immune checkpoint inhibitor, enhancing the body's immune response against tumor cells by blocking the PD-1/PD-L1 pathway. Etoposide is a small molecule that inhibits DNA topoisomerase II, while cisplatin is a platinum-based agent that causes DNA cross-linking, both leading to cell cycle arrest and apoptosis. This specific regimen is being investigated by Fujian Cancer Hospital as a neoadjuvant treatment for patients with resectable stage I-II neuroendocrine cervical carcinoma (NECC), an aggressive and rare variant of cervical cancer. The approach aims to leverage the synergistic effects of immunotherapy and standard-of-care chemotherapy to improve surgical outcomes and long-term survival.

Brand names

Airuika

Other names

karelizumab + etoposide + cisplatincamrelizumab plus etoposide and cisplatinCamrelizumab + EP